



**Fiscal Note**  
**H.B. 487 1st Sub. (Buff)**  
 2023 General Session  
 Sickle Cell Disease  
 by Hollins, S. (Hollins, Sandra.)



**General, Income Tax, and Uniform School Funds**

JR4-4-101

	Ongoing	One-time	Total
Net GF/ITF/USF (rev.-exp.)	\$0	\$(89,100)	\$(89,100)

**State Government**

UCA 36-12-13(2)(c)

Revenues	FY 2023	FY 2024	FY 2025
Total Revenues	\$0	\$0	\$0

Enactment of this legislation likely will not materially impact state revenue.

Expenditures	FY 2023	FY 2024	FY 2025
General Fund, One-time	\$3,000	\$86,100	\$0
Total Expenditures	\$3,000	\$86,100	\$0

Enactment of this legislation may cost the Department of Health and Human Services one-time from the General Fund \$3,000 in FY 2023 and \$86,100 in FY 2024 for staff time to create a report on improving the surveillance and treatment of sickle disease in Utah. The agency has indicated that it can absorb \$400 of the FY 2023 costs and \$15,500 of the FY 2024 costs.

Net All Funds	FY 2023	FY 2024	FY 2025
	\$(3,000)	\$(86,100)	\$0

**Local Government**

UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

**Individuals & Businesses**

UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.

**Regulatory Impact**

UCA 36-12-13(2)(d)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

**Performance Evaluation**

JR1-4-601

This bill does not create a new program or significantly expand an existing program.

**Notes on Notes**

Fiscal notes estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal note is not an appropriation. The Legislature decides appropriations separately.